SLC5A2 and chronic kidney disease: The combination of drugs may have additive benefits to convey kidney and CV protection, for example, as it was reported for the dual use of SGLT2-inhibitor (dapagliflozin) and MRA (eplerenone) in early CKD stages with albuminuria [25].